Turnstone Biologics

Turnstone Biologics is driven by science and innovation

Turnstone’s platform and intellectual property are based on discoveries from leading researchers in the oncolytic viral immunotherapy field including John Bell, Ph.D., Brian Lichty, Ph.D., and David Stojdl, Ph.D. Four Canadian academic institutes, together with the Fight Against Cancer Innovation Trust (FACIT), have advanced Turnstone’s lead immunotherapy product into a Phase I/II clinical development study in advanced cancer patients.